FY2027 EPS Estimates for Inozyme Pharma Raised by Analyst

Inozyme Pharma, Inc. (NASDAQ:INZY) – Investment analysts at HC Wainwright raised their FY2027 earnings per share estimates for shares of Inozyme Pharma in a report issued on Tuesday, March 11th. HC Wainwright analyst E. White now forecasts that the company will post earnings per share of ($0.73) for the year, up from their previous estimate of ($1.57). HC Wainwright has a “Buy” rating and a $16.00 price objective on the stock. The consensus estimate for Inozyme Pharma’s current full-year earnings is ($1.59) per share.

A number of other research firms have also recently commented on INZY. Raymond James lowered their target price on Inozyme Pharma from $24.00 to $12.00 and set an “outperform” rating on the stock in a research note on Wednesday. Piper Sandler lowered their target price on Inozyme Pharma from $30.00 to $23.00 and set an “overweight” rating on the stock in a research note on Tuesday. Needham & Company LLC lowered their target price on Inozyme Pharma from $23.00 to $15.00 and set a “buy” rating on the stock in a research note on Tuesday. Wedbush reiterated an “outperform” rating and set a $7.00 target price (down from $12.00) on shares of Inozyme Pharma in a research note on Monday, March 10th. Finally, Wells Fargo & Company lowered their target price on Inozyme Pharma from $14.00 to $11.00 and set an “overweight” rating on the stock in a research note on Monday, January 13th. Nine investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $14.56.

Inozyme Pharma Price Performance

Shares of NASDAQ:INZY opened at $1.00 on Friday. The company has a current ratio of 7.68, a quick ratio of 7.68 and a debt-to-equity ratio of 0.51. The stock’s fifty day simple moving average is $1.44 and its two-hundred day simple moving average is $3.23. Inozyme Pharma has a 1-year low of $0.98 and a 1-year high of $7.80. The stock has a market cap of $64.24 million, a PE ratio of -0.64 and a beta of 1.32.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in INZY. Harvest Investment Services LLC purchased a new position in Inozyme Pharma during the 4th quarter valued at about $31,000. Graham Capital Management L.P. purchased a new position in Inozyme Pharma during the 4th quarter valued at about $33,000. China Universal Asset Management Co. Ltd. purchased a new position in Inozyme Pharma during the 4th quarter valued at about $38,000. D. E. Shaw & Co. Inc. purchased a new position in Inozyme Pharma during the 4th quarter valued at about $49,000. Finally, ProShare Advisors LLC purchased a new position in Inozyme Pharma during the 4th quarter valued at about $49,000. Hedge funds and other institutional investors own 88.30% of the company’s stock.

About Inozyme Pharma

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.